Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Paclitaxel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 3/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 3/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 3/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 3/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 3/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 3/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 3/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 3/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 3/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 3/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 3/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 3/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 3/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 3/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paclitaxel SCHEMBL1560990 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL760032 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL14580645 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760447 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL18997 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760443 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL13174850 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL17897671 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL22149786 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL177944 | 1.00 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 674 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720329-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SensID GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| WO-2024246014-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SENSID GMBH (DE) | 2024-12-05 | — | — | WO | claimed |
| EP-4467659-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS WITH A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSIS | SensID GmbH (DE) | 2024-11-27 | — | — | EP | claimed |
| WO-2013067543-A1 | METHODS AND COMPOSITIONS FOR ADMINISTERING A SPECIFIC WAVELENGTH PHOTOTHERAPY | FOLLEA INTERNATIONAL LTD. (CN) | 2013-05-10 | — | — | WO | claimed |
| US-20130115180-A1 | Methods And Compositions For Administering A Specific Wavelength Phototherapy | APPLIED BIOLOGY, INC. | 2013-05-09 | — | — | US | claimed |
| US-20070042999-A1 | Phosphate derivatives of pharmaceutical products | VITAL HEALTH SCIENCES PTY. LTD (AU) | 2007-02-22 | — | — | US | claimed |
| EP-1615650-A4 | PHOSPHATE DERIVATIVES OF PHARMACEUTICAL PRODUCTS | VITAL HEALTH SCIENCES PTY LTD (AU) | 2006-06-14 | — | — | EP | claimed |
| CN-1774254-A | Phosphate derivatives of pharmaceutical preparations | VITAL HEALTH SCIENCES PTY LTD (AU) | 2006-05-17 | — | — | CN | claimed |
| EP-1615650-A1 | PHOSPHATE DERIVATIVES OF PHARMACEUTICAL PRODUCTS | Vital Health Sciences Pty Ltd. (AU) | 2006-01-18 | — | — | EP | claimed |
| WO-2004091636-A1 | PHOSPHATE DERIVATIVES OF PHARMACEUTICAL PRODUCTS | VITAL HEALTH SCIENCES PTY LTD (AU) | 2004-10-28 | — | — | WO | claimed |
| EP-4748453-A2 | METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| CN-122075735-A | Therapeutic combinations comprising anti-FOLR 1 immunoconjugates | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122031375-A | Temperature-sensitive hydrogel for post-radiotherapy vaginal repair and preparation method thereof | 吉林大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122005704-A | Composition for repairing immune injury and preparation method and application thereof | 成都中医药大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4727550-A1 | 5-HTR1B MODULATOR FOR USE IN THE TREATMENT OF SOLID TUMOURS | Leukos Biotech, S.L. (ES) | 2026-04-22 | — | — | EP | disclosed |
| WO-2002064214-A2 | ANTI CANCER COMBINATION OF SUBSTITUTED PYRROLES AND PACLITAXEL | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-22 | — | — | WO | disclosed |
| EP-1231939-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1100494-A1 | PHARMACEUTICALLY COMPOSITION COMPRISING AN AQUEOUS SOLUTION OF PACLITAXEL AND ALBUMIN | Novopharm Biotech, Inc. (CA) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001034135-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2000006152-A1 | PHARMACEUTICALLY ACCEPTABLE COMPOSITION COMPRISING AN AQUEOUS SOLUTION OF PACLITAXEL AND ALBUMIN | NOVOPHARM BIOTECH, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042999-A1 | Phosphate derivatives of pharmaceutical products | S100P, PTMS, ALPP | TUBB4A 959/4885TUBB 769/4885TUBA3C 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.